Cannabinoid Biosensors Could Personalize Pain Treatment

Medical cannabis presents clinicians with an unusual dosing problem. Two patients can use comparable amounts of THC or CBD yet experience very different levels of pain relief, sedation, impairment, or no meaningful effect at all. Even the same patient may respond differently depending on the product, administration method, meal timing, other medications, and frequency of cannabis use.

A new scientific review¹ examines whether cannabinoid biosensors could eventually make these responses more predictable. Researchers assessed conventional laboratory techniques alongside emerging electrochemical, optical, colorimetric, immunoassay, and biological sensors designed to detect THC, CBD, and related metabolites.

The technology is advancing rapidly. Some experimental devices can analyze extremely small samples, connect to smartphones, or produce results outside a conventional laboratory. However, the review identifies a more fundamental obstacle: detecting cannabinoids is becoming easier, but interpreting the result remains difficult.

Why Medical Cannabis Dosing Remains Difficult

Therapeutic drug monitoring is already used with medications for which the difference between an ineffective dose and a harmful one may be narrow. Clinicians measure the amount of a drug in a patient’s blood and use established reference ranges to help adjust treatment.

Medical cannabis does not yet have an equivalent system for pain management. There are no universally accepted THC or CBD concentration ranges that reliably identify an effective dose. Cannabinoid levels also do not translate neatly into pain relief, particularly across different products and administration methods.

This uncertainty matters because research into cannabis and chronic pain continues to produce mixed findings. Some studies report meaningful improvements for particular patients or conditions, while others find only modest average benefits. Recent research has associated medical cannabis with reduced opioid consumption, but an association at the population level cannot tell a clinician whether an individual patient has received an appropriate cannabinoid dose.

Biosensors could help fill that information gap, although a concentration reading would be only one part of the answer.

How Cannabinoid Biosensors Work

Conventional cannabinoid analysis relies heavily on laboratory techniques such as liquid chromatography, gas chromatography, and mass spectrometry. These methods can separate and quantify structurally similar cannabinoids and metabolites with high accuracy. They remain the reference standard against which emerging sensors must be tested.

Their disadvantages are practical. Laboratory analysis requires specialized equipment, trained personnel, sample preparation, and time. That limits its usefulness during an appointment or for repeated measurements during everyday treatment.

Biosensors attempt to translate chemical recognition into a rapid and measurable signal. An electrochemical sensor, for example, may detect how THC or CBD changes an electrical response at the surface of an electrode. Optical and fluorescence platforms generate measurable changes in light, while immunoassays use antibodies that recognize a particular cannabinoid or metabolite.

The review identifies portable electrochemical sensors and compact optical or immunoassay platforms as the most promising near-term options. They do not necessarily achieve the lowest experimental detection limits, but they offer a more practical combination of speed, cost, portability, sample volume, and ease of use.

What A Clinically Useful Sensor Would Need To Do

• Distinguish THC, CBD, and clinically relevant metabolites
• Work reliably with authentic patient samples
• Deliver reproducible results across devices and operators
• Remain stable during storage and routine clinical use
• Match validated laboratory measurements closely

Most experimental platforms have not yet satisfied all of these requirements. Many have been demonstrated with prepared solutions, artificial fluids, or biological samples spiked with known cannabinoid concentrations. These tests establish that a sensing mechanism works, but they do not reproduce the complexity of samples collected from patients using cannabis-based treatments.

Blood, Saliva, And Urine Reveal Different Information

The biological sample used by a sensor determines what its result can meaningfully show. Blood, saliva, urine, sweat, breath, and hair are not interchangeable.

Plasma and serum currently provide the most clinically interpretable measurements because they are commonly used in pharmacokinetic studies. However, drawing and processing blood reduces the convenience that makes point-of-care biosensors attractive.

Saliva offers easier collection, but cannabinoid levels in oral fluid may be heavily influenced by the administration method. Smoking, vaporizing, or using an oromucosal product can leave THC inside the mouth, producing a high reading that does not accurately represent systemic exposure. Conversely, saliva screening may fail to detect THC after an oral capsule even when it remains measurable in blood.

Urine generally detects prior exposure through metabolites such as THC-COOH. In chronic users, the detection window can extend for weeks, making it unsuitable for determining whether THC is currently producing pain relief or impairment.

A Sensor Reading Cannot Explain Pain Relief By Itself

One of the review’s most important conclusions is that analytical sensitivity is not the same as clinical usefulness. A device may detect an extremely low THC concentration and still provide little guidance about treatment.

For a result to inform care, it must be connected to the dose, product formulation, administration route, sampling time, pain response, adverse effects, and characteristics of the patient. This is particularly important because cannabinoid exposure can vary dramatically.

Oral THC and CBD undergo digestive and liver metabolism before reaching systemic circulation. Inhaled cannabinoids act more quickly and generally produce different peak concentrations. A high-fat meal can increase CBD exposure severalfold, while frequent cannabis use can alter THC distribution and elimination. Cannabinoids also accumulate in fatty tissues, complicating the interpretation of an isolated measurement.

Drug interactions add another layer. THC and CBD are metabolized through liver enzyme systems involved in processing many prescription drugs. CBD can inhibit some of these enzymes, potentially changing exposure to THC or medications such as warfarin, tacrolimus, and clobazam. The FDA has also investigated CBD safety and liver enzyme elevations, reinforcing the importance of monitoring more than symptom relief when high therapeutic doses are used.

Biosensors May First Become Research Tools

The most realistic early application may not be automated dosing. Instead, portable sensors could help researchers build the evidence needed for future dosing guidance.

Patients could provide repeated samples while recording pain intensity, physical function, sleep quality, side effects, food intake, and product use. Combining those observations with cannabinoid and metabolite concentrations could reveal why similar doses produce different results. This approach would be more informative than a single measurement taken without clinical context.

Emerging therapeutic drug monitoring systems are already being investigated as tools for advancing precision medicine. Cannabinoid monitoring represents an especially demanding test because cannabis products can contain multiple active compounds, and their effects depend on formulation, metabolism, and individual physiology.

Future systems may therefore need to measure several compounds simultaneously, including THC, CBD, the psychoactive THC metabolite 11-OH-THC, and the inactive exposure marker THC-COOH. Measuring only THC could provide an incomplete picture, while measuring only an inactive metabolite could confirm use without revealing current effects.

Artificial Intelligence Could Add Clinical Context

The sensor itself may eventually become only one component of a larger decision-support system. Machine learning could combine cannabinoid measurements with body composition, tolerance, medications, administration method, diet, and reported outcomes. Rather than treating one concentration as universally safe or effective, the system could identify patterns specific to an individual patient.

This possibility is important because medical cannabis care has a broader knowledge problem. A recent survey found substantial support for medical cannabis among healthcare professionals but also exposed a persistent clinical cannabis training gap. Better sensors would generate more data, but clinicians would still need validated frameworks for interpreting it.

Any algorithm would also be limited by the quality of its training data. Feeding poorly validated sensor readings or inconsistent product information into an advanced model would create an appearance of precision without dependable clinical meaning. Standardized sample collection, laboratory comparison, product documentation, and patient outcome tracking must come first.

What Must Happen Before Clinical Adoption

The review makes clear that cannabinoid biosensors are not ready to independently direct pain treatment. Promising devices must be evaluated with authentic samples from patients, compared against established chromatography and mass spectrometry methods, and tested for interference from similar cannabinoids, metabolites, medications, and biological compounds.

Researchers must also establish sensor stability, manufacturing consistency, calibration reliability, and performance across different operators and patient populations. Most importantly, long-term studies must connect measured concentrations with meaningful outcomes rather than cannabinoid exposure alone.

Until those relationships are established, readings should support clinical judgment rather than replace it. A sensor might help confirm that a patient absorbed CBD, identify unexpectedly high THC exposure, or document adherence. It cannot yet determine, on its own, whether a patient should increase or decrease a dose.

From Trial-And-Error Cannabis Use To Measurable Care

Cannabinoid biosensors could eventually make medical cannabis treatment more measurable, consistent, and personalized. Their greatest contribution may be helping medicine move beyond product labels and reported doses toward an understanding of what actually reaches the patient’s bloodstream and how that exposure relates to benefits and risks.

The remaining challenge is not simply engineering a smaller detector. It is building the clinical evidence around that detector. If researchers can connect reliable measurements with pain relief, function, impairment, and adverse effects, biosensors could become part of a more disciplined approach to cannabinoid medicine. Until then, they are best viewed as promising tools for constructing the evidence base that personalized cannabis dosing will require.

References:

^{1. Banik, S., Fales, J., & Kim, J.-H. (2026). Biosensing technologies for cannabinoid monitoring in pain management: Current methods, clinical needs, and translational challenges. Journal of Pharmaceutical and Biomedical Analysis, 281, 117673. https://doi.org/10.1016/j.jpba.2026.117673}